Back to Global NewsPublished: 11 Mar 2026Download AppJoin TelegramWhy Arvinas' ARV-102 Trial Could Flip Parkinson's Investing#Arvinas#ARV-102#Parkinson's disease#PROTAC#Biotech stocks#Neurodegenerative therapiesDownload AppJoin CommunityShare Article